NMR measurement of LDL particle number using the Vantera Clinical Analyzer
| Autor: | Elias J. Jeyarajah, Yuan Xu, Paul J. Braun, Thomas S. Clement, Margery A. Connelly, Irina Shalaurova, Justyna Wolak-Dinsmore, Suzette M. Warner, Steven P. Matyus, Timothy J. Fischer |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Spectrum analyzer
Chromatography Magnetic Resonance Spectroscopy Particle number Routine testing Chemistry Lipoprotein particle analysis Low-density lipoprotein Clinical Biochemistry Analytical chemistry Reproducibility of Results General Medicine Nuclear magnetic resonance spectroscopy Repeatability Cholesterol LDL Cardiovascular disease Lipoprotein particle Assay interference NMR spectroscopy Specimen collection Humans CV risk management |
| Zdroj: | Clinical biochemistry. 47(16-17) |
| ISSN: | 1873-2933 |
| Popis: | Background The Vantera Clinical Analyzer was developed to enable fully-automated, high-throughput nuclear magnetic resonance (NMR) spectroscopy measurements in a clinical laboratory setting. NMR-measured low-density lipoprotein particle number (LDL-P) has been shown to be more strongly associated with cardiovascular disease outcomes than LDL cholesterol (LDL-C) in individuals for whom these alternate measures of LDL are discordant. Objective The aim of this study was to assess the analytical performance of the LDL-P assay on the Vantera Clinical Analyzer as per Clinical Laboratory Standards Institute (CLSI) guidelines. Results Sensitivity and linearity were established within the range of 300–3500 nmol/L. For serum pools containing low, medium and high levels of LDL-P, the inter-assay, intra-assay precision and repeatability gave coefficients of variation (CVs) between 2.6 and 5.8%. The reference interval was determined to be 457–2282 nmol/L and the assay was compatible with multiple specimen collection tubes. Of 30 substances tested, only 2 exhibited the potential for assay interference. Moreover, the LDL-P results from samples run on two NMR platforms, Vantera Clinical Analyzer and NMR Profiler, showed excellent correlation (R 2 = 0.96). Conclusions The performance characteristics suggest that the LDL-P assay is suitable for routine testing in the clinical laboratory on the Vantera Clinical Analyzer, the first automated NMR platform that supports NMR-based clinical assays. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect